Total Payments
$981,950
2024 Payments
$112,073
Companies
36
Transactions
726
Medicare Patients
11,652
Medicare Billing
$11.3M
Payment Breakdown by Category
Other$529,645 (53.9%)
Consulting$282,918 (28.8%)
Travel$96,672 (9.8%)
Research$60,270 (6.1%)
Food & Beverage$11,989 (1.2%)
Education$457.23 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $517,195 | 167 | 52.7% |
| Consulting Fee | $282,918 | 111 | 28.8% |
| Travel and Lodging | $96,672 | 165 | 9.8% |
| Unspecified | $60,270 | 87 | 6.1% |
| Honoraria | $12,450 | 10 | 1.3% |
| Food and Beverage | $11,989 | 176 | 1.2% |
| Education | $457.23 | 10 | 0.0% |
Payments by Type
General
$921,681
639 transactions
Research
$60,270
87 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $283,864 | 175 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $106,928 | 77 | $0 (2023) |
| Merck Sharp & Dohme LLC | $102,656 | 72 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $79,463 | 54 | $0 (2024) |
| PFIZER INC. | $50,107 | 37 | $0 (2024) |
| Amgen Inc. | $48,355 | 25 | $0 (2019) |
| ARRAY BIOPHARMA INC | $45,636 | 37 | $0 (2024) |
| F. Hoffmann-La Roche AG | $38,772 | 18 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $37,715 | 89 | $0 (2024) |
| GENZYME CORPORATION | $34,696 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,073 | 83 | E.R. Squibb & Sons, L.L.C. ($30,023) |
| 2023 | $115,842 | 118 | E.R. Squibb & Sons, L.L.C. ($26,600) |
| 2022 | $157,587 | 111 | E.R. Squibb & Sons, L.L.C. ($90,941) |
| 2021 | $100,783 | 52 | E.R. Squibb & Sons, L.L.C. ($57,503) |
| 2020 | $86,856 | 38 | Novartis Pharmaceuticals Corporation ($17,995) |
| 2019 | $175,835 | 130 | Novartis Pharmaceuticals Corporation ($43,692) |
| 2018 | $67,495 | 55 | F. Hoffmann-La Roche AG ($15,610) |
| 2017 | $165,481 | 139 | Merck Sharp & Dohme Corporation ($34,910) |
All Payment Transactions
726 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,565.00 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,964.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,286.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $699.90 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $124.34 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $425.11 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $154.34 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $326.20 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $35.50 | General |
| 11/04/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $734.58 | General |
| 11/04/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $25.50 | General |
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,048.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $1,089.06 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,352.00 | General |
| Category: Oncology | ||||||
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $83.38 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,717.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $522.88 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% • Category: ONCOLOGY | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,365.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/17/2024 | Immunocore Limited | KIMMTRAK (Drug) | Honoraria | Cash or cash equivalent | $875.00 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,286.00 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $750.19 | General |
| Category: Oncology | ||||||
| 10/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $88.88 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Treatment Patterns Among Patients with Malignant Melanoma in MarketScan claims data 2011- 2016 | Amgen Inc. | $14,037 | 1 |
| REGN3767 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $9,790 | 55 |
| P3 OPTiM Melanoma | Amgen Inc. | $9,515 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,540 | 3 |
| PHASE 1 STUDY OF IMC-CS4 A MONOCLONAL ANTIBODY TARGETED TO THE CSF-1 RECEPTOR -CSF-1R- IN SUBJECTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY OR FOR WHICH NO STANDARD THERAPY IS AVAILABLE | ImClone Systems, LLC | $3,896 | 1 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% | Regeneron Pharmaceuticals, Inc. | $2,222 | 9 |
| A PHASE I TRIAL OF VEMURAFENIB AND IPILIMUMAB IN SUBJECTS WITH V600 BRAF MUTATION-POSITIVE METASTATIC MELANOMA | F. Hoffmann-La Roche AG | $2,047 | 1 |
| Intratumoral Immunotherapy Update 2019 | Amgen Inc. | $1,379 | 1 |
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| PHASE 1 STUDY TO IDENTIFY THE IMMUNOMODULATORY ACTIVITY OF LY3022855 IMC-CS4 IN PATIENTS WITH ADVANCED, REFRACTORY BREAST OR PROSTATE CANCER | Eli Lilly and Company | $977.40 | 1 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $764.08 | 3 |
| A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $713.88 | 2 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $378.20 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Fianlimab Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $39.13 | 1 |
| REGN6569 Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $32.03 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 3,087 | 62,390 | $10.0M | $2.7M |
| 2022 | 43 | 2,801 | 79,479 | $10.8M | $2.9M |
| 2021 | 48 | 2,929 | 98,409 | $12.8M | $3.4M |
| 2020 | 49 | 2,835 | 64,513 | $8.8M | $2.4M |
Total Patients
11,652
Total Services
304,791
Medicare Billing
$11.3M
Procedure Codes
188
All Medicare Procedures & Services
188 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | Office | 2023 | 14 | 6,411 | $3.4M | $889,028 | 26.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 19,005 | $3.1M | $816,105 | 26.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 15 | 27,263 | $2.4M | $641,620 | 27.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 221 | 495 | $294,084 | $72,976 | 24.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 2,700 | $162,000 | $49,612 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 205 | 471 | $200,097 | $49,148 | 24.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 62 | 316 | $167,418 | $37,137 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 130 | 261 | $78,828 | $18,213 | 23.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 158 | $55,674 | $16,119 | 29.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 256 | 717 | $26,529 | $7,414 | 27.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 49 | 67 | $28,369 | $7,406 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $23,189 | $5,778 | 24.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 256 | 745 | $20,115 | $5,664 | 28.2% |
| 82977 | Glutamyltransferase (liver enzyme) level | Office | 2023 | 233 | 581 | $14,525 | $4,096 | 28.2% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 245 | 626 | $13,146 | $3,701 | 28.2% |
| 84550 | Uric acid level, blood | Office | 2023 | 248 | 643 | $10,288 | $2,845 | 27.7% |
| 84100 | Phosphate level | Office | 2023 | 242 | 577 | $9,809 | $2,679 | 27.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 163 | 297 | $5,529 | $2,495 | 45.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 90 | 137 | $8,083 | $2,255 | 27.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 26 | 28 | $8,426 | $2,244 | 26.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 20 | 41 | $10,142 | $2,240 | 22.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 30 | $7,100 | $1,807 | 25.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 21 | 38 | $7,220 | $1,677 | 23.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 28 | 84 | $6,216 | $1,188 | 19.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 17 | 37 | $3,959 | $993.82 | 25.1% |
About Dr. Omid Hamid, M.D
Dr. Omid Hamid, M.D is a Hematology & Oncology healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215966775.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Omid Hamid, M.D has received a total of $981,950 in payments from pharmaceutical and medical device companies, with $112,073 received in 2024. These payments were reported across 726 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($517,195).
As a Medicare-enrolled provider, Hamid has provided services to 11,652 Medicare beneficiaries, totaling 304,791 services with total Medicare billing of $11.3M. Data is available for 4 years (2020–2023), covering 188 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Santa Monica, CA
- Active Since 06/30/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215966775
Products in Payments
- OPDIVO (Biological) $254,432
- LIBTAYO (Biological) $105,425
- MEKINIST (Drug) $89,444
- IMLYGIC (Biological) $47,555
- BRAFTOVI (Drug) $46,907
- Zelboraf (Biological) $44,814
- KIMMTRAK (Drug) $29,688
- Braftovi (Drug) $19,406
- LIBTAYO (Drug) $15,172
- TECENTRIQ (Biological) $12,816
- Lenvima (Drug) $8,548
- TAFINLAR (Drug) $7,192
- KEYTRUDA (Biological) $6,498
- Nubeqa (Drug) $5,240
- XPOVIO (Drug) $5,000
- YERVOY (Biological) $3,300
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $3,178
- Leukine (Drug) $2,000
- MEKTOVI (Drug) $1,408
- ELREXFIO (Drug) $1,270
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Santa Monica
Steven O'day, M.d, M.D
Hematology & Oncology — Payments: $594,773
Hematology & Oncology $594,773
Steven Wong, Md, MD
Hematology & Oncology — Payments: $421,118
Hematology & Oncology $421,118
Silvana Martino, D.o, D.O
Hematology & Oncology — Payments: $179,144
Hematology & Oncology $179,144
Miss. Blanca Ledezma, Msn, Np, MSN, NP
Hematology & Oncology — Payments: $148,836
Hematology & Oncology $148,836
Dr. Arun Singh, M.d, M.D
Hematology & Oncology — Payments: $121,941
Hematology & Oncology $121,941
Dr. William Isacoff, M.d, M.D
Hematology & Oncology — Payments: $108,579
Hematology & Oncology $108,579